Advertisement
Advertisement
U.S. markets open in 8 hours 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5200+0.0200 (+0.57%)
At close: 04:00PM EST
3.4700 -0.05 (-1.42%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close3.5000
Open3.2000
Bid0.0000 x 3000
Ask0.0000 x 800
Day's Range3.2000 - 3.8500
52 Week Range2.2500 - 14.6300
Volume2,065,433
Avg. Volume18,449,693
Market Cap52.997M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.9240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BFRI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biofrontera Inc.
    Daily – Vickers Top Insider Picks for 01/07/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    19 days agoArgus Research
View more
  • GlobeNewswire

    Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond

    WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Board Hermann Lübbert. To our valued stockholders, We would like to extend warm wishes to all of you for a healthy and prosperous 2022. At Biofrontera Inc., we welcomed the New Year with optimism and continued business mom

  • GlobeNewswire

    Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

    WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021. Revenue for the fourth quarter of 2021 is anticipated to be in the range of approximately $9.1 million to $9.2 million, an increase of approximately 7% over the same quarter last year. Revenue for the full

  • GlobeNewswire

    Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January

    WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conferences in January: 2022 Winter Clinical Dermatology Conference at the Grand Hyatt in Kauai, January 14-19, 2022Maui Derm for Dermatologists 2022 at the Grand Wailea, January 24-28, 2022 At each conference, clinical data for B

Advertisement
Advertisement